Cargando…
Effect of Dexrazoxane and Amifostine on the Vertebral Bone Quality of Doxorubicin Treated Male Rats
Doxorubicin (DOX) is widely used in combination cocktails for treatment of childhood hematological cancers and solid tumors. A major factor limiting DOX usage is DOX-induced cardiotoxicity. However, it is not known whether protectants like dexrazoxane (DXR) and amifostine (AMF) can prevent DOX-media...
Autores principales: | Mwale, F, Marguier, G, Ouellet, J.A, Petit, A, Epure, L.M, Antoniou, J, Chalifour, L.E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687116/ https://www.ncbi.nlm.nih.gov/pubmed/19478935 http://dx.doi.org/10.2174/1874325000802010115 |
Ejemplares similares
-
Cisplatin/dexrazoxane/doxorubicin: Neutropenia and thrombocytopenia: case report
Publicado: (2020) -
Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma
por: Narayan, Hari K, et al.
Publicado: (2019) -
Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice
por: Bosman, Matthias, et al.
Publicado: (2023) -
Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562
por: Sargent, J M, et al.
Publicado: (2001) -
Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study
por: QuanJun, Yang, et al.
Publicado: (2017)